AptaTargets signed in May 2025 a licensing agreement with Merck for the clinical development and global commercialisation of ApTOLL, an aptamer with neuroprotective effect for the treatment of ischaem...
En Lainco Pharma siguen innovando para cuidar de ti y de los tuyos. Hoy te presentan Ion Quick, su nuevo complemento alimenticio con electrolitos y glucosa, diseñado para una rehidratación oral segu...
Polymers are emerging as powerful alternatives to viral vectors for DNA delivery, enabling safer and more flexible approaches for DNA vaccines and in vivo CAR-T therapies.
It is the first centre in Spain to achieve this accreditation, which places its operations on a par with those of a pharmaceutical laboratory and consolidates the leadership of the Advanced Therapies ...